Qed Therapeutics Inc.

Achondroplasia

Clinical research in achondroplasia centers on pediatric growth disorders, with attention to long-term safety, tolerability, and changes in standing height Z-score. The sponsor’s trials include children across multiple age ranges, reflecting a sustained interest in skeletal dysplasia and growth-related outcomes.

  • Pediatric growth impairment
  • Long-term treatment safety
  • Height-related efficacy measures

Research activity in this area also includes younger children and infants, indicating focus on early-life management of genetic short stature.

Hypochondroplasia

In hypochondroplasia, the sponsor is active in studies evaluating efficacy and safety in children with short stature and growth potential. The clinical program addresses both school-age children and broader pediatric populations affected by this rare bone growth disorder.

  • Childhood short stature
  • Growth potential assessment
  • Safety and tolerability monitoring

The research portfolio includes extended follow-up in participants who complete earlier treatment periods, supporting continued interest in pediatric endocrine and skeletal care.

The sponsor’s clinical activity is concentrated on FGFR3-related conditions associated with disproportionate short stature, including both achondroplasia and hypochondroplasia. These studies reflect a therapeutic emphasis on disorders driven by abnormal bone development and impaired linear growth.

  • Genetic skeletal dysplasia
  • Disproportionate short stature
  • Childhood bone growth regulation

Trial activity spans infants, children, and adolescents, showing interest in lifespan-relevant pediatric management of rare growth conditions.

Pediatric rare disease therapeutics

The sponsor’s funded trials are focused on rare pediatric diseases with measurable effects on growth and development. The clinical landscape includes outcomes tied to treatment safety, tolerability, and functional growth improvement in children with limited therapeutic options.

  • Rare pediatric disorder treatment
  • Growth and development outcomes
  • Extended pediatric follow-up

Research sites across multiple countries indicate activity in international pediatric clinical research for inherited skeletal conditions.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • A study testing the safety and effectiveness of infigratinib compared to placebo in infants and young children with achondroplasia

    Recruiting

    2 1 1
    Investigated drugs:
    Norway Spain
  • Study on the Effectiveness and Safety of Infigratinib for Children with Hypochondroplasia and Short Stature

    Recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    France Norway Portugal Spain Sweden
  • Study on Long-Term Use of Infigratinib for Children with Achondroplasia

    Recruiting

    2 1 1
    Investigated drugs:
    France Italy Norway Spain
  • Long‑Term Safety and Efficacy of Infigratinib in Children with Hypochondroplasia

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Norway Spain
  • Study on the Effectiveness and Safety of Infigratinib for Children Aged 3 to 17 with Achondroplasia

    Not recruiting

    3 1
    Investigated drugs:
    France Germany Italy Norway Spain